Edwards Lifesciences Investment Purchases decreased by 22.4% to $641.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.0%, from $634.50M to $641.10M. Over 4 years (FY 2021 to FY 2025), Investment Purchases shows an upward trend with a 17.4% CAGR.
An increase indicates a surplus of cash being deployed into financial markets rather than core operations; a decrease may suggest a need for liquidity.
The total cash outflow for the acquisition of debt and equity securities, including marketable securities and other fina...
Large-cap technology firms often show high outflows here as they manage massive cash reserves across global portfolios.
purchases_of_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $299.10M | $345.50M | $907.30M | $74.10M | $40.20M | $188.50M | $13.00M | $3.20M | $3.60M | $1.60M | $700.00K | $1.80M | $0.00 | $517.00M | $381.10M | $634.50M | $624.30M | $1.01B | $826.60M | $641.10M |
| QoQ Change | — | +15.5% | +162.6% | -91.8% | -45.7% | +368.9% | -93.1% | -75.4% | +12.5% | -55.6% | -56.3% | +157.1% | -100.0% | — | -26.3% | +66.5% | -1.6% | +61.2% | -17.9% | -22.4% |
| YoY Change | — | — | — | — | -86.6% | -45.4% | -98.6% | -95.7% | -91.0% | -99.2% | -94.6% | -43.8% | -100.0% | >999% | >999% | >999% | — | +94.7% | +116.9% | +1.0% |